<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093725</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-med-21-10-01</org_study_id>
    <nct_id>NCT05093725</nct_id>
  </id_info>
  <brief_title>CD49 in Optimization The Cologenicity of Mesenchymal Stem Cell Culture Passage</brief_title>
  <official_title>CD49 in Optimization The Cologenicity of Mesenchymal Stem Cell Culture Passage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human mesenchymal stem cells (MSCs) due to their regenerative and immunomodulatory properties&#xD;
      are widely used for the treatment of bone and cartilage damage, cardiovascular,&#xD;
      gastrointestinal, autoimmune, neurodegenerative diseases and cancer .It is shown that the use&#xD;
      of MSCs in therapy is safe and can be effective .In 2006, the International Society for&#xD;
      Cellular Therapy (ISCT) proposed the minimal criteria to define human MSCs. First, MSCs must&#xD;
      be plastic-adherent when maintained in the standard culture conditions. Second MSCs must&#xD;
      express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79a or CD19&#xD;
      and HLA-DR surface molecules.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>evaluation the best passage of MSC culture by CD49 surface marker</measure>
    <time_frame>7 months</time_frame>
    <description>evaluation the best passage of MSC culture by CD49 surface marker</description>
  </primary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Umbilical Cord of Normal Labor</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>flow cytomery</intervention_name>
    <description>take sample of Wharton jelly and culturing it to know the best time for mesenchymal stem cell growth</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        taking umbilical cord of normally labored babies&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        normal babies delivered by normal labor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        diseased or congenital anomalies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>samia s shawky, resident</last_name>
    <phone>01280055734</phone>
    <email>samya_dematri@med.sohag.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hasnaa A Abo-elwafa</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sohag University Hospital</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Osama R ElSherif</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Lv FJ, Tuan RS, Cheung KM, Leung VY. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells. 2014 Jun;32(6):1408-19. doi: 10.1002/stem.1681. Review.</citation>
    <PMID>24578244</PMID>
  </reference>
  <reference>
    <citation>Madrigal M, Rao KS, Riordan NH. A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods. J Transl Med. 2014 Oct 11;12:260. doi: 10.1186/s12967-014-0260-8. Review.</citation>
    <PMID>25304688</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>samia samir shawky</investigator_full_name>
    <investigator_title>resident doctor at clinical pathology in Sohag oncology center</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

